Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8731 |
High Similarity |
NPD4625 |
Phase 3 |
0.8667 |
High Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.8519 |
High Similarity |
NPD4908 |
Phase 1 |
0.8129 |
Intermediate Similarity |
NPD6959 |
Discontinued |
0.8015 |
Intermediate Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.8015 |
Intermediate Similarity |
NPD4749 |
Approved |
0.8 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.7973 |
Intermediate Similarity |
NPD7390 |
Discontinued |
0.7971 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.7929 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.7872 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.7857 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.7848 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7836 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.7823 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.7786 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.7778 |
Intermediate Similarity |
NPD4097 |
Suspended |
0.777 |
Intermediate Similarity |
NPD7003 |
Approved |
0.7762 |
Intermediate Similarity |
NPD1613 |
Approved |
0.7762 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.7744 |
Intermediate Similarity |
NPD8453 |
Clinical (unspecified phase) |
0.7721 |
Intermediate Similarity |
NPD4626 |
Approved |
0.7702 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7674 |
Intermediate Similarity |
NPD2342 |
Discontinued |
0.766 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.7643 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.7607 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7571 |
Intermediate Similarity |
NPD6696 |
Suspended |
0.7566 |
Intermediate Similarity |
NPD7447 |
Phase 1 |
0.7557 |
Intermediate Similarity |
NPD4750 |
Phase 3 |
0.7519 |
Intermediate Similarity |
NPD7635 |
Approved |
0.7518 |
Intermediate Similarity |
NPD1651 |
Approved |
0.7517 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.75 |
Intermediate Similarity |
NPD7040 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD6099 |
Approved |
0.75 |
Intermediate Similarity |
NPD7041 |
Phase 2 |
0.75 |
Intermediate Similarity |
NPD5404 |
Approved |
0.75 |
Intermediate Similarity |
NPD6100 |
Approved |
0.75 |
Intermediate Similarity |
NPD5408 |
Approved |
0.75 |
Intermediate Similarity |
NPD7213 |
Phase 3 |
0.75 |
Intermediate Similarity |
NPD7212 |
Phase 2 |
0.75 |
Intermediate Similarity |
NPD5406 |
Approved |
0.75 |
Intermediate Similarity |
NPD5405 |
Approved |
0.7452 |
Intermediate Similarity |
NPD37 |
Approved |
0.7451 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.7447 |
Intermediate Similarity |
NPD1283 |
Approved |
0.7423 |
Intermediate Similarity |
NPD7852 |
Clinical (unspecified phase) |
0.7417 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7413 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.7407 |
Intermediate Similarity |
NPD7229 |
Phase 3 |
0.7391 |
Intermediate Similarity |
NPD5691 |
Approved |
0.7379 |
Intermediate Similarity |
NPD6812 |
Clinical (unspecified phase) |
0.7358 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.7357 |
Intermediate Similarity |
NPD1611 |
Approved |
0.7351 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.7343 |
Intermediate Similarity |
NPD4624 |
Approved |
0.7338 |
Intermediate Similarity |
NPD2532 |
Approved |
0.7338 |
Intermediate Similarity |
NPD2534 |
Approved |
0.7338 |
Intermediate Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.7338 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7338 |
Intermediate Similarity |
NPD2533 |
Approved |
0.7329 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7312 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7312 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7312 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7303 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.7297 |
Intermediate Similarity |
NPD1607 |
Approved |
0.7296 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.7296 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7287 |
Intermediate Similarity |
NPD940 |
Approved |
0.7287 |
Intermediate Similarity |
NPD846 |
Approved |
0.7285 |
Intermediate Similarity |
NPD7037 |
Approved |
0.7267 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.7261 |
Intermediate Similarity |
NPD5808 |
Clinical (unspecified phase) |
0.726 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7254 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.7254 |
Intermediate Similarity |
NPD1669 |
Approved |
0.7254 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.7234 |
Intermediate Similarity |
NPD1281 |
Approved |
0.7234 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.723 |
Intermediate Similarity |
NPD5124 |
Phase 1 |
0.723 |
Intermediate Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.7229 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7226 |
Intermediate Similarity |
NPD6671 |
Approved |
0.7222 |
Intermediate Similarity |
NPD6584 |
Phase 3 |
0.7215 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7214 |
Intermediate Similarity |
NPD2286 |
Discontinued |
0.7209 |
Intermediate Similarity |
NPD1242 |
Phase 1 |
0.7206 |
Intermediate Similarity |
NPD4869 |
Clinical (unspecified phase) |
0.7206 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.7206 |
Intermediate Similarity |
NPD1398 |
Phase 1 |
0.72 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.72 |
Intermediate Similarity |
NPD1509 |
Clinical (unspecified phase) |
0.719 |
Intermediate Similarity |
NPD3892 |
Phase 2 |
0.7188 |
Intermediate Similarity |
NPD8455 |
Phase 2 |
0.7183 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.7178 |
Intermediate Similarity |
NPD6746 |
Phase 2 |
0.7174 |
Intermediate Similarity |
NPD7340 |
Approved |
0.7171 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.717 |
Intermediate Similarity |
NPD7411 |
Suspended |
0.7168 |
Intermediate Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.7164 |
Intermediate Similarity |
NPD5451 |
Approved |
0.7162 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.7162 |
Intermediate Similarity |
NPD1240 |
Approved |
0.7162 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.7162 |
Intermediate Similarity |
NPD2979 |
Phase 3 |
0.7162 |
Intermediate Similarity |
NPD2238 |
Phase 2 |
0.716 |
Intermediate Similarity |
NPD3749 |
Approved |
0.7153 |
Intermediate Similarity |
NPD3094 |
Phase 2 |
0.7135 |
Intermediate Similarity |
NPD8054 |
Approved |
0.7135 |
Intermediate Similarity |
NPD8053 |
Approved |
0.7133 |
Intermediate Similarity |
NPD5327 |
Phase 3 |
0.7115 |
Intermediate Similarity |
NPD7422 |
Clinical (unspecified phase) |
0.7114 |
Intermediate Similarity |
NPD5735 |
Approved |
0.7108 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7108 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7108 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7101 |
Intermediate Similarity |
NPD709 |
Approved |
0.7099 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7086 |
Intermediate Similarity |
NPD3748 |
Approved |
0.7086 |
Intermediate Similarity |
NPD4108 |
Discontinued |
0.7083 |
Intermediate Similarity |
NPD8651 |
Approved |
0.7078 |
Intermediate Similarity |
NPD7466 |
Approved |
0.7076 |
Intermediate Similarity |
NPD8313 |
Approved |
0.7076 |
Intermediate Similarity |
NPD8312 |
Approved |
0.7071 |
Intermediate Similarity |
NPD3091 |
Approved |
0.7063 |
Intermediate Similarity |
NPD2232 |
Approved |
0.7063 |
Intermediate Similarity |
NPD2233 |
Approved |
0.7063 |
Intermediate Similarity |
NPD2230 |
Approved |
0.7059 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7047 |
Intermediate Similarity |
NPD4140 |
Approved |
0.7044 |
Intermediate Similarity |
NPD7458 |
Discontinued |
0.7044 |
Intermediate Similarity |
NPD3226 |
Approved |
0.703 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7024 |
Intermediate Similarity |
NPD7177 |
Discontinued |
0.7019 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7014 |
Intermediate Similarity |
NPD6582 |
Phase 2 |
0.7014 |
Intermediate Similarity |
NPD6583 |
Phase 3 |
0.7013 |
Intermediate Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.7006 |
Intermediate Similarity |
NPD4160 |
Clinical (unspecified phase) |
0.7 |
Intermediate Similarity |
NPD3020 |
Approved |
0.6993 |
Remote Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.6993 |
Remote Similarity |
NPD3092 |
Approved |
0.6993 |
Remote Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.6988 |
Remote Similarity |
NPD3787 |
Discontinued |
0.6975 |
Remote Similarity |
NPD2801 |
Approved |
0.6975 |
Remote Similarity |
NPD5929 |
Approved |
0.6957 |
Remote Similarity |
NPD7615 |
Clinical (unspecified phase) |
0.6954 |
Remote Similarity |
NPD4579 |
Clinical (unspecified phase) |
0.6954 |
Remote Similarity |
NPD6353 |
Approved |
0.6948 |
Remote Similarity |
NPD1549 |
Phase 2 |
0.6946 |
Remote Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.6943 |
Remote Similarity |
NPD1511 |
Approved |
0.6937 |
Remote Similarity |
NPD4005 |
Discontinued |
0.6934 |
Remote Similarity |
NPD228 |
Approved |
0.6928 |
Remote Similarity |
NPD2438 |
Suspended |
0.6923 |
Remote Similarity |
NPD8099 |
Discontinued |
0.6923 |
Remote Similarity |
NPD8252 |
Approved |
0.6923 |
Remote Similarity |
NPD8251 |
Approved |
0.6918 |
Remote Similarity |
NPD4339 |
Clinical (unspecified phase) |
0.6912 |
Remote Similarity |
NPD3022 |
Approved |
0.6912 |
Remote Similarity |
NPD3021 |
Approved |
0.6908 |
Remote Similarity |
NPD4538 |
Approved |
0.6908 |
Remote Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.6908 |
Remote Similarity |
NPD4536 |
Approved |
0.6906 |
Remote Similarity |
NPD497 |
Approved |
0.6901 |
Remote Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.6899 |
Remote Similarity |
NPD844 |
Approved |
0.6899 |
Remote Similarity |
NPD2859 |
Approved |
0.6899 |
Remote Similarity |
NPD7446 |
Clinical (unspecified phase) |
0.6899 |
Remote Similarity |
NPD2860 |
Approved |
0.6893 |
Remote Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.689 |
Remote Similarity |
NPD4581 |
Clinical (unspecified phase) |
0.6884 |
Remote Similarity |
NPD5535 |
Approved |
0.6883 |
Remote Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.6883 |
Remote Similarity |
NPD5762 |
Approved |
0.6883 |
Remote Similarity |
NPD2346 |
Discontinued |
0.6883 |
Remote Similarity |
NPD3540 |
Phase 1 |
0.6883 |
Remote Similarity |
NPD5763 |
Approved |
0.6882 |
Remote Similarity |
NPD8156 |
Discontinued |
0.6875 |
Remote Similarity |
NPD3705 |
Approved |
0.6871 |
Remote Similarity |
NPD1465 |
Phase 2 |
0.686 |
Remote Similarity |
NPD7240 |
Approved |
0.6855 |
Remote Similarity |
NPD5261 |
Clinical (unspecified phase) |
0.6855 |
Remote Similarity |
NPD1940 |
Clinical (unspecified phase) |
0.6855 |
Remote Similarity |
NPD1512 |
Approved |
0.6855 |
Remote Similarity |
NPD6090 |
Discontinued |
0.6855 |
Remote Similarity |
NPD4319 |
Phase 2 |
0.6853 |
Remote Similarity |
NPD4059 |
Approved |
0.6853 |
Remote Similarity |
NPD5125 |
Phase 3 |
0.6853 |
Remote Similarity |
NPD5126 |
Approved |
0.6853 |
Remote Similarity |
NPD3095 |
Discontinued |
0.6853 |
Remote Similarity |
NPD3019 |
Approved |
0.6848 |
Remote Similarity |
NPD7075 |
Discontinued |
0.6848 |
Remote Similarity |
NPD4055 |
Discovery |
0.6846 |
Remote Similarity |
NPD7095 |
Approved |
0.6846 |
Remote Similarity |
NPD288 |
Approved |
0.6845 |
Remote Similarity |
NPD8051 |
Clinical (unspecified phase) |
0.6835 |
Remote Similarity |
NPD496 |
Approved |
0.6835
|
Remote Similarity |
NPD495 |
Approved |